Scarica l'app Stockscreener
226.88
1.61%
-3.71
Precedente Chiudi:
$230.59
Aprire:
$230.87
Volume 24 ore:
770.21K
Relative Volume:
0.84
Capitalizzazione di mercato:
$14.25B
Reddito:
$4.44B
Utile/perdita netta:
$29.49M
Rapporto P/E:
-12,330.43
EPS:
-0.0184
Flusso di cassa netto:
$1.19B
1 W Prestazione:
-1.01%
1M Prestazione:
-0.83%
6M Prestazione:
+33.67%
1 anno Prestazione:
+106.93%
Intervallo 1D:
$225.55
$231.78
Intervallo di 1 settimana:
$225.55
$236.71
Portata 52W:
$105.00
$243.32
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
226.88 | 14.49B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Ripresa | Raymond James | Outperform |
| 2026-02-27 | Iniziato | Barclays | Overweight |
| 2025-11-24 | Downgrade | UBS | Buy → Neutral |
| 2025-07-15 | Iniziato | Deutsche Bank | Buy |
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
[144] Jazz Pharmaceuticals plc SEC Filing - Stock Titan
JAZZ’s Zepzelca fails to meet primary goal in lung cancer study - MSN
How Investors Are Reacting To Jazz (JAZZ) Zepzelca Failing Phase 3 LAGOON Survival Endpoint - simplywall.st
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study - Yahoo Finance
Jazz Pharmaceuticals plc (JAZZ): Investor Outlook with Strong Buy Ratings and 11% Potential Upside - DirectorsTalk Interviews
Jazz Pharma announces late-stage trial setback for lung cancer therapy - MSN
Jazz, AstraZeneca, Astellas: Foreign healthcare's strongest quant picks - MSN
Insider Sell: Neena Patil Sells Shares of Jazz Pharmaceuticals P - GuruFocus
Jazz Pharmaceuticals (JAZZ) Shares Decline After Zepzelca Trial Results - GuruFocus
[Form 4] Jazz Pharmaceuticals plc Insider Trading Activity - Stock Titan
Jazz Pharmaceuticals lung cancer drug fails late-stage trial By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals (JAZZ) Reports Phase 3 Trial Results for Ze - GuruFocus
Jazz Pharmaceuticals' Zepzelca misses primary goal in Phase 3 LAGOON trial - grafa.com
Jazz Pharmaceuticals lung cancer drug fails main trial goal - Reuters
Jazz Pharmaceuticals stock falls after lung cancer trial fails By Investing.com - Investing.com Australia
Jazz Pharmaceuticals stock falls after lung cancer trial fails - Investing.com
Jazz Pharmaceuticals’ Zepzelca fails phase 3 lung cancer trial By Investing.com - Investing.com Australia
Jazz Pharmaceuticals’ Zepzelca fails phase 3 lung cancer trial - Investing.com
Jazz Pharma's lung cancer drug fails late-stage trial - marketscreener.com
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer - PR Newswire
MIdWestOne Financial Group Inc. Cuts Stock Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
UBS upgrades Jazz Pharmaceuticals (JAZZ) - MSN
New Xywav Data And FDA Ruling Put Jazz Valuation In Focus - Yahoo Finance
Daiwa Securities Group Inc. Has $1.46 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Allianz Asset Management GmbH Boosts Stock Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst - Benzinga
JAZZ Maintained by B of A Securities -- Price Target Raised to $307 - GuruFocus
Jazz Pharmaceuticals plc Stock 12‑Month Price Target Raised to $259.28, Implies 13% Upside - TradingView
GW&K Investment Management LLC Sells 27,068 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM) - The Globe and Mail
BofA raises Jazz Pharmaceuticals stock price target on Ziihera sales By Investing.com - Investing.com UK
Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Franklin Resources Inc. - MarketBeat
Bernstein SocGen reiterates Jazz Pharmaceuticals stock rating at Market Perform - Investing.com UK
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Presents a Decent Value Opportunity with Strong Valuation and Growth Potential - ChartMill
Truist assumes Jazz Pharmaceuticals stock with buy on oncology growth By Investing.com - Investing.com UK
Jazz Pharmaceuticals plc ($JAZZ) President, CEO and Director 2025 Pay Revealed - Quiver Quantitative
Jazz Pharmaceuticals (JAZZ) sets 2026 AGM on directors, pay and share issuance powers - Stock Titan
These healthcare stocks have maintained strong buy ratings for months - MSN
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Los Angeles Capital Management LLC - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Navigating a 6.14% Potential Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Capital World Investors Has $453.32 Million Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
CenterBook Partners LP Buys New Shares in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Xywav And Ziihera Updates And Strong Quarterly Results - simplywall.st
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jazz Pharmaceuticals Public Limited Company Trade Ideas — XETR:J7Z - TradingView
Bank of New York Mellon Corp Purchases 715,361 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals (NASDAQ: JAZZ) CEO donates 600 shares - Stock Titan
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia - marketscreener.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Flashes Perfect Minervini Trend Template Score with 116% Annual Surge - ChartMill
Globeflex Capital L P Takes $780,000 Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Jazz Pharmaceuticals Plc Azioni (JAZZ) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Patil Neena M | EVP & Chief Legal Officer |
Jun 10 '26 |
Sale |
231.83 |
1,200 |
278,196 |
51,549 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):